Recurrent life-threatening thromboembolism and catastrophic antiphospholipid syndrome in a patient despite sufficient oral anticoagulation

被引:11
作者
Miesbach, W
Scharrer, I
Asherson, RA
机构
[1] Goethe Univ Frankfurt, Univ Hosp, D-60590 Frankfurt, Germany
[2] Univ Cape Town, Hlth Sci Ctr, Cape Town & Rosebank Clin, Rheumat Dis Unit, Johannesburg, South Africa
关键词
anticoagulation; antiphospholipid syndrome; catastrophic antiphospholipid syndrome; myocardial infarction; recurrent pulmonary thromboembolism;
D O I
10.1007/s10067-004-0864-0
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
We report on a 32-year old female patient with primary antiphospholipid syndrome (PAPS) and several thromboembolic events despite stable doses of oral anticoagulation, good patient compliance and maintained INR values of >3. Over the preceding 3 years the patient had presented a wide spectrum of manifestations of APS, including recurrent venous and arterial thromboses, cardiac, gynecological (HELLP syndrome), neurological involvements, livedo reticularis, a mild thrombocytopenia and the most feared manifestation of the catastrophic antiphospholipid syndrome (CAPS). Life-threatening bilateral subdural bleeding occurred while she was anticoagulated. The clinical features appeared to be refractory to oral anticoagulation with phenprocoumon. They were life threatening on each occasion and she developed repetitive episodes of organ damage with cardiac insufficiency (NYHA III), pulmonary hypertension and other residual defects. Even during heparinization recurrent thromboembolism supervened as well as livedo reticularis of the extremities. Lupus anticoagulants (LAC), anticardiolipin (aCL) antibodies and anti-beta(2)-glycoprotein-1 (beta(2)GPI) titers were all markedly elevated. This case report shows that recurrent episodes of thrombosis can occur despite seemingly adequate anticoagulation in patients with CAPS.
引用
收藏
页码:256 / 261
页数:6
相关论文
共 48 条
[1]   Prophylaxis of the antiphospholipid syndrome:: a consensus report [J].
Alarcón-Segovia, D ;
Boffa, MC ;
Branch, W ;
Cervera, R ;
Gharavi, A ;
Khamashta, M ;
Shoenfeld, Y ;
Wilson, W ;
Roubey, R .
LUPUS, 2003, 12 (07) :499-503
[2]  
AlSayegh FA, 1997, J RHEUMATOL, V24, P1716
[3]   Catastrophic antiphospholipid syndrome -: Clinical and laboratory features of 50 patients [J].
Asherson, RA ;
Cervera, R ;
Piette, JC ;
Font, J ;
Lie, JT ;
Burcoglu, A ;
Lim, K ;
Muñoz-Rodríguez, FJ ;
Levy, RA ;
Boué, F ;
Rossert, J ;
Ingelmo, M .
MEDICINE, 1998, 77 (03) :195-207
[4]   Catastrophic antiphospholipid syndrome: international consensus statement on classification criteria and treatment guidelines [J].
Asherson, RA ;
Cervera, R ;
de Groot, PG ;
Erkan, D ;
Boffa, MC ;
Piette, JC ;
Khamashta, MA ;
Shoenfeld, Y .
LUPUS, 2003, 12 (07) :530-534
[5]  
ASHERSON RA, 1992, J RHEUMATOL, V19, P508
[6]  
Asherson RA, 2000, J RHEUMATOL, V27, P12
[7]  
BAJAJ SP, 1983, BLOOD, V61, P684
[8]  
BRANDT JT, 1995, THROMB HAEMOSTASIS, V74, P1185
[9]   Stroke and the antiphospholipid syndrome: consensus meeting Taormina 2002 [J].
Brey, RL ;
Chapman, J ;
Levine, SR ;
Ruiz-Irastorza, G ;
Derksen, RHWM ;
Khamashta, M ;
Shoenfeld, Y .
LUPUS, 2003, 12 (07) :508-513
[10]   Antiphospholipid syndrome -: Clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients [J].
Cervera, R ;
Piette, JC ;
Font, J ;
Khamashta, MA ;
Cervera, R ;
Piette, JC ;
Font, J ;
Khamashta, MA ;
Shoenfeld, Y ;
Camps, MT ;
Jacobsen, S ;
Lakos, G ;
Tincani, A ;
Kontopoulou-Griva, I ;
Galeazzi, M ;
Meroni, PL ;
Derksen, RHWM ;
de Groot, PG ;
Gromnica-Ihle, E ;
Baleva, M ;
Mosca, M ;
Bombardieri, S ;
Houssiau, F ;
Gris, JC ;
Quéré, I ;
Hachulla, E ;
Vasconcelos, C ;
Roch, B ;
Fernández-Nebro, A ;
Boffa, MC ;
Hughes, GRV ;
Ingelmo, M .
ARTHRITIS AND RHEUMATISM, 2002, 46 (04) :1019-1027